Publications:76
Video Visit Available
Accepting New Patients
- Mount Sinai Doctors
- Treats Adults
- Video Visit Available
- Accepting New Patients
Max W Sung, MD
Cancer (Oncology), Hematology-Oncology
About Me
Max Sung, MD, is Associate Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. He has been on the faculty at Mount Sinai since 1987.
Dr. Sung specializes in gastrointestinal cancers including liver, bile duct, pancreas, esophagus, stomach, colon/rectum, and anus cancers. His approach to cancer treatment is multi-disciplinary, and involves collaboration with other specialties such as surgery, interventional radiology, and radiation therapy.
Dr. Sung has held numerous leadership roles at Mount Sinai, including Medical Director of The Ruttenberg Treatment Center and Chair of the Data and Safety Monitoring Committee for cancer clinical trials.
Dr. Sung is involved in clinical cancer research and has authored numerous peer-reviewed publications on innovative and translational treatments.
Dr. Sung is fluent in English and Chinese (Cantonese and Mandarin), and has a working knowledge of German and French.
Language
Chinese (Mandarin), English, Chinese (Cantonese)
Position
PROFESSOR | Medicine, Hematology and Medical Oncology
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
Clinical Focus
- Chemotherapy
- Colon Cancer
- Colorectal Cancer
- Esophageal Cancer
- Liver Cancer
- Pancreatic Cancer
- Stomach Cancer
Education
MD, Albert Einstein College of Medicine
Internship, Internal Medicine
Montefiore Medical Center
Residency, Internal Medicine
Montefiore Medical Center
Fellowship, Hematology
Montefiore Medical Center
Certifications
American Board of Internal Medicine
Research
Dr. Sung is currently conducting clinical trials of immunotherapy in patients with advanced colorectal and breast cancers using gene transfer therapy. He is also involved in clinical trials of suicide gene therapy and differentiation therapies for colorectal cancer, and anti-angiogenesis therapy for hepatocellular carcinoma.
Dr. Sung actively participates in multi-modality treatment approaches (surgery/radiation/chemotherapy) to cancers of the liver, colon-rectum, carcinoid, pancreas, esophagus, stomach and anal cancers, and is also experienced in regional treatment modalities such as hepatic arterial chemotherapy/chemoembolization and intraperitoneal chemotherapy.
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - HealthPlus Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Magnacare-Health Care
- Medicare - NJ
- Medicare - NY
- Metroplus
- Multiplan PHCS
- NJ Medicaid
- NY Medicaid
- Oscar
- Oxford - Freedom and Liberty
- Partners Health Plan
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VNSNY Select Health Medicaid
- VillageCareMax
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma. Kirema Garcia-Reyes, Ricki A. Gottlieb, Kartikeya M. Menon, Vivian Bishay, Rahul Patel, Rajesh Patel, Scott Nowakowski, Max W. Sung, Thomas U. Marron, William H. Gansa, Jack Zhang, Sahitya C. Raja, Daniel Shilo, Aaron Fischman, Robert Lookstein, Edward Kim. Journal of Vascular and Interventional Radiology
- Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study. Fabio Piscaglia, Kenji Ikeda, Ann Lii Cheng, Masatoshi Kudo, Masafumi Ikeda, Valery Breder, Baek Yeol Ryoo, Kalgi Mody, Min Ren, Zahra Ramji, Max W. Sung. Cancer
- Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Josep M. Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek Yeol Ryoo, Zhenggang Ren, Gianluca Masi, Mariusz Kwiatkowski, Ho Yeong Lim, Jee Hyun Kim, Valeriy Breder, Hiromitsu Kumada, Ann Lii Cheng, Peter R. Galle, Shuichi Kaneko, Anran Wang, Kalgi Mody, Corina Dutcus, Leonid Dubrovsky, Abby B. Siegel, Richard S. Finn, Simone Strasser, Alexander Thompson, Aflah Roohullah, William Sievert, Vladimir Andelkovic, Jennifer Knox, Janine Davies, Jamil Asselah, Mayur Brahmania, Habeeb Majeed, Luis Villanueva, Patricio Yanez Weber, Marcelo Garrido, Gonzalo Ignacio Pizarro, Nicolas Yanez, Shuangyan Ou, Hongming Pan, Zhiqiang Meng, Kangsheng Gu, Xi Chen, Tao Zhang, Chunyi Hao, Peiguo Cao, Yabing Guo, Max Sung. The Lancet Oncology
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Sung during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- DAVA Oncology
- AstraZeneca AB
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.